150592
Last Update Posted: 2021-06-10
Recruiting has ended
All Genders accepted | 6 Years-17 Years |
182 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17
The purpose of this study is to determine the effects of SPD503 compared to placebo on tasks of sustained attention in children and adolescents aged 6-17 diagnosed with ADHD.
Eligibility
Relevant conditions:
Attention Deficit Disorder With Hyperactivity
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov